Clinical trials
Graft Versus Host Disease clinical trials
Below are recruiting graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 121 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT04886726RecruitingPhase 1
New medicine to prevent graft-versus-host disease after transplant
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Detroit, MichiganAges 18–70 - NCT05236062Recruiting
Exercise during steroid treatment for GVHD
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
Boston, MassachusettsAges 18 years+ - NCT05289167RecruitingPhase 1/Phase 2
Medicines to prevent graft-versus-host disease after a transplant
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
New Hyde Park, New YorkAges 14–100 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05675930RecruitingPhase 2
Light therapy for mouth GVHD after a stem cell transplant
This Phase 2 study tests a special light treatment (photobiomodulation) to improve oral graft-versus-host disease (GVHD) after a stem cell transplant. It may help people whose mouth symptoms have not improved with at least one prior treatment.
Bethesda, MarylandAges 4 years+ - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Stanford, CaliforniaAges 3 years+ - NCT05919511Recruiting
Questionnaire study for people at risk after stem cell transplant
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
Birmingham, AlabamaAges 18 years+ - NCT05922761RecruitingPhase 2
Belumosudil for lung scar prevention or treatment after transplant
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Stanford, CaliforniaAges 18 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+ - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06046248RecruitingPhase 2
Belumosudil and Rituximab for first-time chronic GVHD treatment
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
Atlanta, GeorgiaAges 18 years+ - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06300320RecruitingPhase 2
TQ05105 for chronic graft-versus-host disease
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hefei, AnhuiAges 18–70 - NCT06321003Recruiting
Testing AI to detect early oral cancer with light scans
This trial uses a special light-based scanner (OCT) and artificial intelligence to help diagnose early signs of mouth cancer or precancer. It aims to see if this combination can make diagnosis easier and more accurate.
PalermoAges 18–99 - NCT06392711RecruitingPhase 1
Stem cell therapy for dry mouth not from radiation
This trial tests a new treatment using special cells (mesenchymal stromal cells) from your own bone marrow to help with dry mouth that is not caused by radiation. The goal is to see if it can increase saliva production and improve quality of life.
Madison, WisconsinAges 18–90 - NCT06423131Recruiting
Comparing two types of stem cell transplants for children
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
Shanghai, Shanghai MunicipalityAges 2 months–18 years - NCT07689630RecruitingPhase 3
Antibody to prevent GVHD in half-matched stem cell transplant
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
Wuhan, HubeiAges 18–75 - NCT06615050RecruitingPhase 3
Comparing two drug combinations for stem cell transplant
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Palo Alto, CaliforniaAges 18 years+ - NCT06619561RecruitingPhase 2
Testing vimseltinib for chronic graft versus host disease
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Duarte, CaliforniaAges 18 years+ - NCT06626737RecruitingPhase 2
Testing dapagliflozin to prevent GVHD after stem cell transplant
This trial tests whether adding dapagliflozin (a diabetes medication) to standard care can help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for adults who are about to receive a transplant from a half-matched or unrelated donor.
Suzhou, JiangsuAges 18–65 - NCT06649201Recruiting
Study of vaginal health after stem cell transplant
This study looks at how stem cell transplants affect the vagina, especially if you develop a condition called graft-versus-host disease (GVHD). Researchers will examine the vagina and test its natural germs (microbiome) to better understand and possibly improve treatment.
Cleveland, OhioAges 18–70
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for graft versus host disease?
- Yes. Clin2 currently lists 121 recruiting graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.